Concise Reviews: Cancer Stem Cells: From Concept to Cure

Kyle Matchett, T. R. Lappin

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


n 1953, noting a remarkable consistency between the agents causing mutations and those associated with cancer, Carl Nordling, a Finnish-born architect, proposed that cancer results from an accumulation of genetic mutations. It is now generally accepted that inherited mutations and environmental carcinogens can lead to the development of premalignant clones. After further mutations, one cell reaches a critical state which confers a survival or growth advantage over normal cells. Such cells have the ability to initiate a malignant tumour. They share many of the features of normal stem cells, including the capacity for self-renewal and differentiation, and are widely termed cancer stem cells (CSCs). Although CSCs have been well characterized in hematological malignancies, their existence in some other tissues has been questioned. Here, we review recent work in which stem cells and stem cell-like cells have been used to investigate the pathogenesis of cancer and potential anticancer treatment strategies, in the context of both hematological and somatic tissue disease.
Original languageEnglish
Pages (from-to)2563-2570
JournalStem Cells
Issue number10
Early online date15 Sep 2014
Publication statusPublished - Oct 2014


Dive into the research topics of 'Concise Reviews: Cancer Stem Cells: From Concept to Cure'. Together they form a unique fingerprint.

Cite this